SCHEMBL21683294

SCHEMBL21683294

Cc1nc(-c2ccc(CNC(=O)c3cc(CC(C)C)nn3C)cc2)no1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ KCNT1 Q5JUK3 3/20 0.46
▸ PLK1 P53350 1/20 0.46
▸ CTSL P07711 1/20 0.45
▸ CTSB P07858 1/20 0.45
▸ CTSS P25774 1/20 0.45
▸ CTSK P43235 1/20 0.45
▸ PPARG P37231 2/20 0.45
▸ PPARD Q03181 2/20 0.45
▸ PPARA Q07869 2/20 0.45
▸ PHGDH O43175 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ KIFC1 Q9BW19 1/20 0.40
▸ MAPT P10636 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ HDAC4 P56524 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21702468 0.88 HDAC4 (0.46) L3MBTL1KCNT1PPARGPPARDPPARA
SCHEMBL21702522 0.86 L3MBTL1 (0.52) L3MBTL1PLK1CTSLCTSBCTSS
SCHEMBL21702506 0.78 L3MBTL1 (0.52) L3MBTL1PLK1POLBKMT2AMAPT
SCHEMBL19463739 0.76 HDAC4 (0.59) HDAC1HDAC6HDAC4
SCHEMBL20108994 0.76 L3MBTL1 (0.49) L3MBTL1PPARGPPARDPPARAPHGDH
SCHEMBL21702505 0.76 L3MBTL1 (0.43) L3MBTL1PPARGPPARDPPARAPHGDH
SCHEMBL21683299 0.74 PLK1 (0.58) PLK1CTSLCTSBCTSSCTSK
SCHEMBL23780470 0.73 HDAC6 (0.62) PLK1PPARALMNAHDAC1HDAC6
SCHEMBL23291895 0.73 PLK1 (0.57) PLK1CTSLCTSBCTSSCTSK
SCHEMBL8252393 0.71 S1PR1 (0.56) L3MBTL1PLK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486255-B2 Modulators of RAS GTPase TOSK, INC. (US) 2025-12-02 — — US disclosed
US-20240279206-A1 Modulators of RAS GTPase TOSK, INC. 2024-08-22 — — US disclosed
US-11945803-B2 Modulators of RAS GTPase TOSK, INC. (US) 2024-04-02 — — US disclosed
WO-2020033413-A2 MODULATORS OF RAS GTPASE TOSK, INC. (US) 2020-02-13 — — WO disclosed
WO-2020033413-A2 MODULATORS OF RAS GTPASE TOSK, INC. (US) 2020-02-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486255-B2 Modulators of RAS GTPase KRAS, HRAS, NRAS L3MBTL1 3281/4885KCNT1 4402/4885PLK1 123/4885
US-11945803-B2 Modulators of RAS GTPase KRAS, HRAS, NRAS L3MBTL1 3281/4885KCNT1 4402/4885PLK1 123/4885
US-20240279206-A1 Modulators of RAS GTPase KRAS, HRAS, NRAS L3MBTL1 3281/4885KCNT1 4402/4885PLK1 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback